Cancer Immunology, Immunotherapy

, Volume 61, Issue 1, pp 127–135

Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses

Focussed Research Review

DOI: 10.1007/s00262-011-1173-5

Cite this article as:
Kalos, M. Cancer Immunol Immunother (2012) 61: 127. doi:10.1007/s00262-011-1173-5

Abstract

A central role for T cells in the control of cancer has been supported by both animal models and clinical observations. Accordingly, the development of potent anti-tumor T cell immunity has been a long-standing objective of immunotherapy. Emerging data from clinical trials that test T cell immune-modulatory agents and genetically engineered and re-targeted T cells have begun to realize the profound potential of T cell immunotherapy to target cancer. This review will focus on a description of recent conceptual and technological advances for the genetic engineering of T cells to enhance anti-tumor T cell immunity through the introduction of tumor-specific receptors, both Chimeric Antigen Receptors (CAR) and T cell receptors (TcR), as well as an overview of emerging data from ongoing clinical trials that highlight the potential of these approaches to effect dramatic and potent anti-tumor immunity.

Keywords

Chimeric antigen receptorT cell receptorAdoptive T cell transferImmunotherapyGene transferCIMT 2011

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Department of Pathology and Laboratory Medicine, Perelman School of Medicine, Abramson Family Cancer Research InstituteUniversity of PennsylvaniaPhiladelphiaUSA